Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials

Neuroepidemiology

Volumn 20, Issue 2, 2001, Pages 51-56

  Rockwood, Kenneth ^a,b   Macknight, Chris ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Centre for Health Care of the Elderly   (Canada)

Author keywords

Alzheimer's disease; Clinical importance; Controlled trials

Indexed keywords

DONEPEZIL; METRIFONATE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; CLINICAL RESEARCH; DEMENTIA; HUMAN; NEUROPSYCHOLOGICAL TEST; REPRODUCIBILITY; REVIEW; STATISTICAL ANALYSIS;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0035015897     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054761     Document Type: Review

References (41)

1. Rogers SL, Farlow MR, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
2. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer disease. A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158:1021-1031.
3. Marcusson J, Rother M, Kittner B, Rössner M, Smith R, Babic T, Folnegovic-Šmalc V, Möller H, Labs K, on behalf of the European Propentofylline Study Group: A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 1997;8:320-328.
4. Sano M, Ernesto C, Thomas RG, Klauber MR, Schaffen K, Grundman M, Woodhury P, Growdon J, Cotman C, Pfeiffer E, Schneider L, Thal LJ, for the members of the Alzheimer's Disease Cooperative Study: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336: 1216-1222.
5. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka B, Gulanski B: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
6. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group; A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
7. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin H, Hartman R, Gharabawi M, on behalf of the B303 Exelon Study Group: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-640.
8. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I: Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of Phase III trials. Dement Geriatr Cogn Disord 1998;9(suppl 1): 36-43.
9. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H, Rogers S, Friedhoff L, and the International Donepezil Study Group: The effects of donepezil in Alzheimer's disease - Results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244.
10. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, and the Metrifonate Study Group: Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221.
11. Mayeux R, Sano M: Treatment of Alzheimer's disease. N Engl J Med 1999;341:1670-1679.
12. Allen H: Anti-dementia drugs. Int J Geriatr Psychiatry 1999;14:239-243.
13. Anonymous: Donepezil update. Drugs Ther Bull 1998;36:60-61.
14. Qizilbash N, Schneider L, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntii T: Evidence-Based Dementia: A Practical Guide to Diagnosis and Management. Oxford, Blackwell, 2001.
15. Warner JP: Donepezil improved cognitive and global function in mild-to-moderate Alzheimer's disease (commentary). Evid Based Med 1998;3:155.
16. Goodin DS: Perils and pitfalls in the interpretation of clinical trials: A reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999;18:53-63.
17. Johnston KC: What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology 1999;18:167-173.
18. Leber PD: Developing safe and effective antidementia drugs; in Bercker R, Giacobini E (eds): Alzheimer Disease: From Molecular Biology to Therapy. Boston, Birkhäuser, 1997.
19. Rockwood K: Use of global assessment measures in dementia drug trials. J Clin Epidemiol 1994;47:101-103.
20. Knopman DS, Knapp MJ, Gracon SI, Davis CS: The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44: 2315-2321.
21. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M. Thomas R, Ferris SH, and the Alzheimer's Disease Cooperative Study: Validity and reliability of the Alzheimer's disease cooperative study - Clinical global impression of change. Alzheimer Dis Assoc Disord 1997;11(suppl 2): S22-S32.
22. Gélinas I, Gauthier L, McIntryre M, Gauthier S: Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther 1999;53:471-481.
23. Mohr E, Feldman H, Gauthier S: Canadian guidelines for the development of antidementia therapies: A conceptual summary. Can J Neurol Sci 1995;22:62-71.
24. Spilker B: Summary of principles and procedures to follow, and development and use of clinical judgment; in Spilker B: Guide to Clinical Trials. New York, Raven Press, 1991.
25. Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Intern Med 1993;118:622-629.
26. Guyatt GH, Sackett DL, Cook DJ, for the Evidence-Based Medicine Working Group: Users' guides to the medical literature. Part II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994;271:59-63.
27. Hayward RS, Wilson MC, Tunis SR, Bass EB, Guyatt G, for the Evidence-Based Medicine Working Group: Users' guides to the medical literature. Part VIII. How to use clinical practice guidelines. A. Are the recommendations valid? JAMA 1995;274:570-574.
28. Hill AB: A Short Textbook of Medical Statistics, ed 11. London, Hodder and Stoughton, 1984.
29. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. New Jersey, Erlbaum, 1988.
30. Gardner MJ, Altman DG (eds): Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London, British Medical Journal, 1989.
31. Liang MH, Fossel AH, Larson MG: Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990;28:632-642.
32. Furukawa TA: From effect size to number needed to treat. Lancet 1999;353:1680.
33. Laupacis A, Sackett DL, Robert RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318: 1728-1733.
34. Fang C-T, Sau W-Y: From effect size into number needed to treat. Lancet 1999;354:597-598.
35. Scholten RJ, de Beurs E, Bouter LM: From effect size into number needed to treat. Lancet 1999;354:598.
36. Feinstein AR: Clinimetrics. New Haven, Yale University Press, 1987.
37. Schneider LS, Olin JT: Clinical global impression of change: Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr 1996;8:277-288.
38. Rockwood K, Stolee P, Howard K, Mallery L: Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology 1996;15:330-338.
39. Bogardus ST, Bradley EH, Tinetti ME: A taxonomy for goal setting in the care of persons with dementia. J Gen Intern Med 1998;13: 675-680.
40. Hollis S, Campbell F: What is meant by intention to treat analysis? BMJ 1999;319:670-674.
41. Winblad B, Paritis N: Memantine in severe dementia: Results of the 9M-DE57 study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.